| Non-Small Cell Lung Carcinoma
Rybrevant vs Alecensa
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Rybrevant vs Alecensa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAlecensa has a higher rate of injection site reactions vs Rybrevant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Alecensa but not Rybrevant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rybrevant
Alecensa
At A Glance
Intravenous
Weekly x 4-5 weeks, then every 2-3 weeks
Bispecific EGFR/MET antibody
Oral
Twice daily
ALK/RET tyrosine kinase inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma (EGFR Exon 19 Del or L858R, first-line with lazertinib) 1,050 mg (<80 kg) or 1,400 mg (>=80 kg) IV weekly for 5 weeks (Week 1 split over Day 1 and Day 2), then every 2 weeks starting Week 7.
Non-Small Cell Lung Carcinoma (EGFR Exon 19 Del or L858R, post-TKI with chemotherapy) 1,400 mg (<80 kg) or 1,750 mg (>=80 kg) IV weekly for 4 weeks (Week 1 split over Day 1 and Day 2), then 1,750 mg (<80 kg) or 2,100 mg (>=80 kg) every 3 weeks starting Week 7, in combination with carboplatin AUC 5 every 3 weeks for up to 12 weeks and pemetrexed 500 mg/m2 every 3 weeks.
Non-Small Cell Lung Carcinoma (EGFR Exon 20 insertion, first-line with chemotherapy) 1,400 mg (<80 kg) or 1,750 mg (>=80 kg) IV weekly for 4 weeks (Week 1 split over Day 1 and Day 2), then 1,750 mg (<80 kg) or 2,100 mg (>=80 kg) every 3 weeks starting Week 7, in combination with carboplatin AUC 5 every 3 weeks for up to 12 weeks and pemetrexed 500 mg/m2 every 3 weeks.
Non-Small Cell Lung Carcinoma (EGFR Exon 20 insertion, post-platinum as single agent) 1,050 mg (<80 kg) or 1,400 mg (>=80 kg) IV weekly for 5 weeks (Week 1 split over Day 1 and Day 2), then every 2 weeks starting Week 7.
Non-Small Cell Lung Carcinoma (adjuvant) 600 mg orally twice daily with food for a total of 2 years or until disease recurrence or unacceptable toxicity following tumor resection of ALK-positive NSCLC (tumors >= 4 cm or node positive).
Non-Small Cell Lung Carcinoma (metastatic) 600 mg orally twice daily with food until disease progression or unacceptable toxicity; reduce to 450 mg orally twice daily for severe hepatic impairment (Child-Pugh C).
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Rash (72-90%), nail toxicity (45-71%), infusion-related reaction (42-64%), fatigue (32-51%), musculoskeletal pain (30-47%), stomatitis (26-43%), edema (27-43%), nausea (21-45%), constipation (23-39%), decreased appetite (24-36%), diarrhea (15-31%), vomiting (12-25%), VTE (36% in combination with lazertinib), paresthesia (35% in combination with lazertinib), hemorrhage (25% in combination with lazertinib), dry skin (25% in combination with lazertinib), pruritus (24% in combination with lazertinib), COVID-19 (21-26%), dyspnea (37% as single agent), cough (17-25%), paronychia (50% as single agent).
Serious Infusion-related reactions including anaphylaxis, interstitial lung disease/pneumonitis, venous thromboembolic events (11% in combination with lazertinib), dermatologic reactions including toxic epidermal necrolysis, ocular toxicity.
Postmarketing Anaphylaxis/anaphylactic reactions.
Most common (>=20%) Hepatotoxicity, constipation, fatigue, myalgia, edema, rash, cough
Serious Hepatotoxicity, ILD/pneumonitis, renal impairment, bradycardia, severe myalgia and CPK elevation, hemolytic anemia, pneumonia
Pharmacology
Amivantamab-vmjw is a bispecific antibody that binds EGFR and MET extracellular domains, disrupting ligand binding and receptor degradation, and targeting tumor cells for immune-mediated destruction via ADCC and trogocytosis.
Alectinib is a tyrosine kinase inhibitor that targets ALK and RET; it inhibits ALK phosphorylation and ALK-mediated activation of downstream signaling proteins STAT3 and AKT, with the major active metabolite M4 showing similar in vitro potency and activity against multiple mutant forms of ALK, including mutations identified in NSCLC tumors that have progressed on crizotinib.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rybrevant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Alecensa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Rybrevant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Alecensa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Rybrevant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Alecensa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAlecensa Access Solutions Bridge Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RybrevantView full Rybrevant profile
AlecensaView full Alecensa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.